DCP1A and infection: Inhibition of NFκB activity through pharmacological inhibitors (i.e., TPCA-1 and BAY 11-7082) did not affect XRN1-DCP1a-mediated antiviral activities and XRN1 aggregation upon infection with CVB3, a positive ssRNA virus (Supplementary Fig. 7f, g).